Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
In the AlphaLISA® SureFire® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.
AlphaLISA® SureFire® Ultra™ kits are compatible with:
Alpha SureFire® kits can be used for:
|Assay Target Class||Phosphoprotein|
|Product Brand Name||AlphaLISA SureFire Ultra|
|Quantity in a Package Amount||100.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System, Cardiovascular, Neuroinflammation|
|Unit Size||100 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn: ...
In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.
Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA ...
Life science researchers are always working toward the next breakthrough discovery. For scientists working on GPCRs, speed is everything. And when it comes to drug discovery, overcoming the challenge of decreasing assay development time and accelerating your research, is necessary for success.
G protein coupled-receptors (GPCRs) are one of the most intensively studied drug targets, with up to one-third of all marketed therapeutics acting by binding to GPCRs. Therapies that target GPCRs include both agonist and antagonists that are used in the treatment of disease in nearly every major ...